Company Description
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics.
Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system.
The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency.
In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza.
Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 111 |
| CEO | Joseph Payne |
Contact Details
Address: 10285 Science Center Drive San Diego, California 92121 United States | |
| Phone | 858 900 2660 |
| Website | arcturusrx.com |
Stock Details
| Ticker Symbol | ARCT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001768224 |
| CUSIP Number | 03969T109 |
| ISIN Number | US03969T1097 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Joseph E. Payne M.Sc. | Founder, President, Chief Executive Officer and Director |
| Dr. Padmanabh Chivukula Ph.D. | Founder, Chief Scientific Officer, Chief Operating Officer and Secretary |
| Joseph Roberts | Principal Accounting Officer and Controller |
| Lance Kurata | Chief Legal Officer |
| Dennis M. Mulroy | Chief Financial Officer |
| Neda Safarzadeh | Vice President and Head of IR/PR and Marketing |
| Natasha O. Bowman | Chief Human Resources Officer |
| Kevin T. Skol | Chief Business Officer |
| Dr. Igor Smolenov M.D., Ph.D. | Chief Development Officer |
| Dr. Ye Zhang | Chief Regulatory and Quality Assurance Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 7, 2026 | SCHEDULE 13G/A | Filing |
| Sep 23, 2026 | 8-K | Current Report |
| Aug 25, 2026 | 8-K | Current Report |
| Aug 6, 2026 | 10-Q | Quarterly Report |
| Aug 6, 2026 | 8-K | Current Report |
| Jul 2, 2026 | 8-K | Current Report |
| Jun 5, 2026 | 8-K | Current Report |
| May 7, 2026 | 10-Q | Quarterly Report |
| May 7, 2026 | 8-K | Current Report |
| May 7, 2026 | SCHEDULE 13G/A | Filing |